Aβ Pharmacological Chaperones

Aβ peptide small molecule chaperones

Reducing and/or inhibiting the aggregation of Aβ is one of the main therapeutic strategies against Alzheimer's disease (AD). The use of small molecules to reduce and inhibit this aggregation process has high potential as a therapeutic approach through the prevention of the formation of toxic oligomers. Cantabio's small molecules from its CB401 program bind to the native monomeric peptide, with the aim of reducing their misfolding and aggregation through stabilizing and promoting its functional native state. Therapeutic targeting of the monomeric state of Aβ peptides by small molecules has, however, been a major challenge because of their heterogeneous conformational properties. Nevertheless, Cantabio's unique screening approach has been successful in identifying novel small molecules that bind to monomeric Aβ. Cantabio is currently studying and further developing these molecules in relevant AD cellular and in vivo models.

Representations of Aβ native states